Du lundi au vendredi de 8H à 19H au (33) (0)9 52 93 38 78

Envoyer votre communiqué

24 | Communiqué de presse

Press release displayed 2017 times


Juvisé Pharmaceuticals successfully syndicated its EUR 213 million financing in less than one month

Published on 04/02/2020 à 12:41

The French speciality pharmaceutical company, Juvisé Pharmaceuticals is pleased to announce its successful syndication of its EUR 213 million debt package supporting the acquisition of Arimidex® and Casodex® from AstraZeneca, with the collaboration of Société Générale and HSBC, acting as Physical Bookrunners and Mandated Lead Arrangers, BNP Paribas, acting as Mandated Lead Arranger and Lazard acting as financial advisor to Juvisé Pharmaceuticals.

pdf version press release
PDF version

On the back of a strong support from both relationship lenders and institutional investors, syndication was wrapped following a successful and oversubscribed early-bird phase. The covenanted financing is comprised of a EUR 128 million TLB alongside a EUR 85 million TLA. This syndication was made possible through the collaboration with Juvisé Pharmaceuticals financial partners, with whom the company relies on long-term partnership characterized by openness and trust.

This successful syndication is another important step in Juvisé Pharmaceuticals development. It reasserts the company ability to leverage all debt capital instruments to fulfil its growth ambition, while keeping the flexibility and independence in decision making allowed by its privately held structure.

Frédéric Mascha, Founder and President of Juvisé Pharmaceuticals, declared “we are very pleased that our acquisition debt package was successfully syndicated in this oversubscribed early-bird phase and we would like to thank our financial partners for the trust they have shown in our project. We are proud to see that our commitment towards physicians, patients, and our Pharma partners convinced renowned financial institutions to support our ambitious development plan”. 

About Arimidex® and Casodex®

Arimidex® (anastrozole) and Casodex® (bicalutamide) are hormone treatments for breast and prostate cancer. The two products are recognized as pillar in those cancer treatments and essential for both patients and physicians. 

On 19th December 2019, Juvisé Pharmaceuticals acquired the rights of Arimidex® and Casodex® in 45 countries in Europe and a number of Middle Eastern and African markets. 

About Juvisé Pharmaceuticals

Founded in 2008, Juvisé Pharmaceuticals is specialised in manufacturing, distributing and marketing its own branded pharmaceutical products. Juvisé focuses in offering treatments in: (i) Cardiology, (ii) Neuro-Psychiatry and (iii) Oncology. 

The company business model consists in acquiring branded assets from large pharmaceutical companies like Novartis, AstraZeneca or Sigma Tau and optimising value creation through maximization of product life cycle.
11 years after its creation, Juvisé Pharmaceuticals has become a recognized international company commercializing its own treatments in 75 countries around the word. 

For more information, please visit juvisepharmaceuticals.com.

Communiqué publié par Lacour Soline
Published on 04/02/2020 à 12:41 sur 24presse.com
Lacour Soline
Juvisé Pharmaceuticals


Press release copyrights free 24presse.com

Send email to
Lacour Soline

Company : Juvisé Pharmaceuticals

Press contact

Lacour Soline
Juvisé Pharmaceuticals


un communiqué
de presse
Lancer une diffusion

Derniers communiqués de presse de la catégorie "finance"